InMed Pharmaceuticals Financials

InMed Pharmaceuticals Stock Summary

InMed Pharmaceuticals competes with Rave Restaurant, Dominos Pizza, Yum Brands, Westrock Coffee, and Bt Brands. InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada. INMED PHARMACEUTICALS operates under Biotechnology classification in the United States and is traded on OTC Exchange.

InMed Pharmaceuticals Key Financial Ratios

Generally speaking, InMed Pharmaceuticals' financial ratios allow both analysts and investors to convert raw data from InMed Pharmaceuticals' financial statements into concise, actionable information that can be used to evaluate the performance of InMed Pharmaceuticals over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that InMed Pharmaceuticals reports annually and quarterly.

InMed Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining InMed Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare InMed Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across InMed Pharmaceuticals competition to find correlations between indicators driving InMed Pharmaceuticals's intrinsic value. More Info.InMed Pharmaceuticals is currently regarded as number one stock in return on equity category among related companies. It is currently regarded as number one stock in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value InMed Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for InMed Pharmaceuticals' OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the InMed Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in census. Note that the InMed Pharmaceuticals information on this page should be used as a complementary analysis to other InMed Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

If you are still planning to invest in InMed Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the InMed Pharmaceuticals' history and understand the potential risks before investing.